2023 SABCS Highlights

 

Review presentations on research findings presented by Dana-Farber physician-scientists at this year's San Antonio Breast Cancer Symposium (SABCS), held on December 5-9 in San Antonio, Texas. SABCS is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.


Heather Parsons, MD, MPH Discusses Liquid Biopsy

Dana-Farber's Heather Parsons, MD, MPH, discusses a new study showing liquid biopsy could reliably determine whether a patient's breast cancer is HER2-positive or --negative.

Paolo Tarantino, MD Discusses RELIEVE Study

Dana-Farber's Paolo Tarantino, MD, presented results from the RELIEVE study showing patients with metastatic breast cancer receiving trastuzumab deruxtecan fared best if they had HER2+ disease or stable HER2-low disease.

Kate Dibble, PhD Discusses Ovarian Function Suppression

Dana-Farber's Heather Parsons, MD, MPH, discusses a new study showing liquid biopsy could reliably determine whether a patient's breast cancer is HER2-positive or --negative.

 

Press Releases

Potentially targetable fusion RNAs may be more common in metastatic breast cancer than previously realized

Immunotherapy plus standard therapy can increase progression-free survival in patients with HER2+ metastatic breast cancer

Risk that metastatic breast cancer will spread to the brain varies with subtype of the disease

 

 Additional Resources

Dana-Farber Researchers to Present Findings at 2023 San Antonio Breast Cancer Symposium

Breast Cancer Treatment Guidelines developed by Dana-Farber on how to best utilize certain newly approved treatments

Listen to Unraveled, Dana-Farber’s podcast exploring the mysteries of the science of cancer